Back to Dermatology
Dermatologyv1978Evidence-Based

Psoriasis Area and Severity Index (PASI)

Quantifies the severity of psoriasis by combining assessment of lesion severity and affected body surface area. This standardized measurement tool evaluates four body regions (head, arms, trunk, legs) with scoring for erythema, induration, and desquamation, providing an objective assessment for clinical practice and research.

Clinical Input Parameters

score
score
score
score
score
score
score
score
score
score
score
score
score
score
score
score
Clinical Assessment
Awaiting Parameters
pasi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Psoriasis Area and Severity Index (PASI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within dermatology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

PASI = 0.1 × (E_h + I_h + D_h) × A_h + 0.2 × (E_a + I_a + D_a) × A_a + 0.3 × (E_t + I_t + D_t) × A_t + 0.4 × (E_l + I_l + D_l) × A_l

Clinical Pearls & Practice Notes

  • Gold standard for psoriasis severity assessment in clinical practice and research
  • Severity scoring: 0=none, 1=slight, 2=moderate, 3=severe, 4=very severe
  • Area scoring: 0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%
  • Body surface area weights: Head 0.1, Arms 0.2, Trunk 0.3, Legs 0.4
  • Total score range: 0-72 points (higher scores indicate more severe disease)
  • PASI 75 (75% improvement) is considered good therapeutic response
  • PASI 90 (90% improvement) is considered excellent therapeutic response
  • PASI 100 indicates complete clearance of psoriasis lesions
  • Less sensitive for mild psoriasis and localized disease
  • Requires experienced clinician for consistent scoring
  • Does not assess nail involvement or quality of life impact
  • Inter-rater reliability improves with training and experience
  • Used as primary endpoint in most psoriasis clinical trials
  • May underestimate disease severity in dark-skinned patients due to erythema assessment
  • Consider complementary assessments like BSA, PGA, and DLQI for comprehensive evaluation

Evidence & Literature Citations

  1. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44. doi: 10.1159/000250839.
  2. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-9. doi: 10.1016/j.jaad.2004.04.012.
  3. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194-9. doi: 10.1159/000083509.
  4. Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:10-6. doi: 10.1111/j.1468-3083.2009.03562.x.

Score Interpretation Ranges

Mild0 – 5 pts

Mild psoriasis

Moderate5 – 10 pts

Moderate psoriasis

Severe10 – 20 pts

Severe psoriasis

Very Severe20 – 72 pts

Very severe psoriasis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.